TLS/FUS-ERG fusion gene in acute lymphoblastic leukemia with t(16;21)(p11;q22) and monitoring of minimal residual disease

Leuk Lymphoma. 2005 Dec;46(12):1833-5. doi: 10.1080/10428190500162203.


This study reports a 1-year-old boy with precursor B cell acute lymphoblastic leukemia (ALL) carrying t(16;21)(p11;q22). Reverse transcriptase-polymerase chain reaction (RT-PCR) and direct sequence analysis showed TLS/FUS-ERG chimeric mRNA with a novel junctional pattern of exon 7 of TLS/FUS and exon 6 of ERG. He did not respond to ALL-oriented therapy. Complete remission (CR) was achieved by chemotherapy oriented for acute myeloid leukemia. Allogenic bone marrow transplantation was done and he has been in CR for 24 months. TLS/FUS-ERG chimeric mRNA was not detected after CR. This is the first report of an ALL patient with a TLS/FUS-ERG fusion transcript.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Base Sequence
  • Chromosome Mapping
  • Chromosomes, Human, Pair 16*
  • Chromosomes, Human, Pair 21*
  • Cytarabine / administration & dosage
  • Etoposide / administration & dosage
  • Exons
  • Humans
  • Idarubicin / administration & dosage
  • Infant
  • Male
  • Neoplasm, Residual / genetics*
  • Oncogene Proteins, Fusion / genetics*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • RNA-Binding Protein FUS / genetics*
  • Translocation, Genetic*
  • Treatment Outcome


  • Oncogene Proteins, Fusion
  • RNA-Binding Protein FUS
  • TLS-ERG fusion protein, human
  • Cytarabine
  • Etoposide
  • Idarubicin